Viking Therapeutics, Inc (VKTX) Stock Price

VKTXStock
$25.17−27.53%52W
Market Cap$3.20B
P/E—
PEG Ratio—
Div yield—
Beta0.71

VKTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-39.04%
Price vs S&P 500 (4W)-15.08%
VGM Score39.70

VKTX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$1.21-$1.10+8.85%(+$0.11)
Q1 2026-$0.91-$1.37-50.51%(-$0.46)
Q4 2025-$0.90-$1.38-53.10%(-$0.48)
Q3 2025-$0.67-$0.81-20.07%(-$0.14)
Q2 2025-$0.44-$0.58-31.61%(-$0.14)

VKTX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.23
4.23
4.23

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
VKTXViking Therapeutics, Inc
——D————$25.17
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Viking Therapeutics, Inc

Viking Therapeutics is a biopharmaceutical company developing treatments for metabolic and endocrine disorders. Its clinical pipeline includes VK2809 and VK0214, oral selective thyroid hormone receptor beta agonists, and VK5211, an oral selective androgen receptor modulator, each targeting unmet medical needs in hormonal conditions.